HIF1A and neoplasm: This is supported by studies suggesting hypoxic tumours may respond to Bortezomib (Shin et al, 2008) and Amphotericin B (Yeo et al, 2006), which suppress HIF-1α activity by re-enforcing FIH-mediated inhibition of p300 recruitment.